Popular terms

Dimethyl topics
Physiologic
Hydrochloric Acid
Fresnel Zone
Aberration
Ophthalmic
Liquid Crystal
Imaging System
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Chloric Acid
Tartaric Acid
Fumaric Acid
Antagonist
Bradykinin
Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dimethyl patents



      

This page is updated frequently with new Dimethyl-related patent applications.




Date/App# patent app List of recent Dimethyl-related patents
05/19/16
20160137894 
 Non-azeotropic fluid mixture for air conditioning devices patent thumbnailnew patent Non-azeotropic fluid mixture for air conditioning devices
The composition of the mixture contains at least one polymerisation inhibitor agent (hydroquinone, benzotriazole, dimethyl-t-butylphenol).. .

05/19/16
20160137844 
 Carbazole dioxazine pigment and a  its preparation patent thumbnailnew patent Carbazole dioxazine pigment and a its preparation
The pigment is synthesized from 3-nitro-n-ethylcarbazole. The first step is nitration of 3-nitro-n-ethylcarbazole to form 3,6-dinitro-n-ethylcarbazole which is reduced to form 3-amino-6-nitro-n-ethylcarbazole.

05/19/16
20160137683 
 Method for preparing epirubicin and intermediate thereof patent thumbnailnew patent Method for preparing epirubicin and intermediate thereof
The present invention provides a method for preparing epirubicin and an intermediate adaptive to the method. The preparation method may include: reacting tert-butyldimethylsilyl chloride with n-trifluoroacetyl adriamycin to obtain a first compound n-trifluoroacetyl-14-o-tert-butyldimethylsilyl adriamycin; oxidizing the first compound to obtain a second compound 4′-ketone-n-trifluoroacetyl-14-o-tert-butyldimethylsilyladriamycin; reducing the second compound to obtain a third compound n-trifluoroacetyl-14-o-tert-butyldimethylsilyl epirubicin; and performing deprotection and hydrolysis reactions on the third compound to obtain epirubicin.
Zhejiang Hisun Pharmaceutical Co., Ltd.


05/19/16
20160137589 
 Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease patent thumbnailnew patent Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.. .
Jsc Grindeks


05/19/16
20160137587 
 Transition-metal-free n-arylation of tertiary amines using arynes patent thumbnailnew patent Transition-metal-free n-arylation of tertiary amines using arynes
The present invention relates to transition-metal-free process for the synthesis of tertiary arylamines comprises coupling reaction between arynes and n,n-dimethyl aniline compounds in presence of 18-crown-6, kf and thf.. .
Council Of Scientific & Industrial Research


05/19/16
20160136280 
 Stable intravenous formulation patent thumbnailnew patent Stable intravenous formulation
A stable lyophilized formulation for intravenous administration of the compound 4-{[(2r, 3s, 55)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)- pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid 1-[2-(2-methoxy-ethoxy)-ethoxycarbonyloxy]-ethyl ester is provided.. .
Hoffmann-la Roche Inc.


05/19/16
20160135477 
 Ready-to-drink tea beverages with reduced benzene and methods for making same patent thumbnailnew patent Ready-to-drink tea beverages with reduced benzene and methods for making same
A ready-to-drink tea beverage contains tea extract, aerated water and benzoate, such as a benzoic acid salt. The beverage and/or the aerated water can contain at least 5.0 ppm dioxygen (o2) and preferably at least about 5.0 ppm o2.

05/12/16
20160133672 
 Hybrid perovskite with adjustable bandgap patent thumbnailHybrid perovskite with adjustable bandgap
A method is provided for preparing a thin film of perovskite material having an adjustable bandgap. The method forms a thin film of material having the formula bx2, where anionic part x is a halide, and where the cation b is lead (pb), tin (sn), or germanium (ge).
Sharp Laboratories Of America, Inc.


05/12/16
20160131985 
 Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus patent thumbnailElectrophotographic photosensitive member, process cartridge, and electrophotographic apparatus
Provided is an electrophotographic photosensitive member, including in the following order: a support; a charge-generating layer; and a charge-transporting layer, in which: the charge-generating layer includes a gallium phthalocyanine crystal in which an organic compound is contained; the organic compound is at least one compound selected from the group consisting of dimethyl sulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide, and n-methylpyrrolidone; a content of the organic compound is 0.1% by mass or more and 1.5% by mass or less with respect to a mass of gallium phthalocyanine in the gallium phthalocyanine crystal; and the charge-transporting layer comprises at least one compound selected from the group consisting of a compound represented by the formula (1), a compound represented by the formula (2), a compound represented by the formula (3), and a compound represented by the formula (4).. .
Canon Kabushiki Kaisha


05/12/16
20160131658 
 Method and kit for assessing viable cells patent thumbnailMethod and kit for assessing viable cells
The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells, such as viability. The present invention relates to the use of various optionally substituted reporter compounds particularly detectable upon their reaction with thiol-containing species present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead, stressed and apoptotic) cells.
Chemometec A/s


05/12/16
20160130272 

Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders


Crystalline form, form n-2, of n,ndicyclopropyl-4-(1,5-dimethyl-1hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (compound i) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising form n-2 of compound i as well as a method of using the form n-2 of compound i in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


05/12/16
20160129031 

Pyrazole derivative and use thereof for medical purposes


The present invention provides pyrazole derivatives, uses thereof for medical purposes and so on. More particularly, the present invention relates to pharmaceuticals useful for the prevention or treatment of constipation, which comprise as an active ingredient 3-(3-{4-[3-(β-d-glucopyranosyloxy)-5-isopropyl-1h-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof.
Kissei Pharmaceutical Co., Ltd.


05/12/16
20160129009 

High purity diaminophenothiazinium compounds including methylthioninium chloride (mtc)


This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including methythioninium chloride (mtc) (also known as methylene blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (nos); nitrosyl reduction (nr); thiosulfonic acid formation (tsaf); oxidative coupling (oc); cr(vi) reduction (cr); isolation and purification of zwitterionic intermediate (iapozi); ring closure (rc); chloride salt-formation (csf); one of: sulphide treatment (st); dimethyldithiocarbamate treatment (dt); carbonate treatment (ct); ethylenediaminetetraacetic acid treatment (edtat); organic extraction (oe); and recrystallisation (rx).
Wista Laboratories Ltd.


05/12/16
20160129003 

Pharmaceutical combinations


A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, and (b) an anaplastic lymphoma kinase inhibitor, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the treatment or prevention of proliferative diseases; to pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination.. .
Novartis Ag


05/12/16
20160128952 

Pharmaceutical combination


A combination comprising as components (a) the compound 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) paracetamol or a derivative thereof, a pharmaceutical formulation and a dosage form comprising said combination as well as a method of treating pain, e.g. Chronic or acute pain, characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration..
Gruenenthal Gmbh


05/05/16
20160124329 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus, and chlorogallium phthalocyanine crystal and producing the same


An electrophotographic photosensitive member includes a support and a photosensitive layer in this order. The photosensitive layer contains a chlorogallium phthalocyanine crystal represented by formula (1) in which at least one organic compound selected from n,n-dimethylformamide and dimethyl sulfoxide is contained.
Canon Kabushiki Kaisha


05/05/16
20160124328 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


An electrophotographic photosensitive member wherein a charge generating layer of the electrophotographic photosensitive member includes a gallium phthalocyanine crystal in which an organic compound is contained, wherein the organic compound is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and a charge transporting layer of the electrophotographic photosensitive member includes a polycarbonate resin having structural units represented by formulae (1) and (2).. .
Canon Kabushiki Kaisha


05/05/16
20160122938 

Chemically stable, stain-, abrasion- and temperature-resistant, easy-to-clean metalware for use in elevated temperatures


A metalware for use in elevated temperatures, where the surface of the said ware is coated with a layer which is a hydrolysis and polycondensation product of a composition comprising tetraethoxy silane (teos), methyl trimethoxy silane (mtms), dimethyl siloxane (dms), inorganic filler and polar solvent where the said composition comprises 1,3-dialkyl imidazolium alkyl sulfate.. .
Eksen Makine Sanayi Ve Ticaret A.s.


05/05/16
20160122375 

Immobilized metathesis tungsten catalysts and use thereof in olefin metathesis


Compound of formula (i) wherein m is w; r1 is h, aryl, heteroaryl, alkyl, or heteroalkyl, optionally substituted, respectively; r2 and r3 can be the same or different and are alkyl, alkenyl, heteroalkyl, heteroalkenyl, aryl, or heteroaryl, optionally substituted, respectively, or hydrogen; r5 is a residue r6—x—, wherein r6 is alkyl, aryl, heteroalkyl, heteroaryl, optionally substituted, respectively; (r7, r8, r9)si; wherein r7, r8, r9 are independently alkyl, alkoxy, phenyl or phenoxy, optionally substituted, respectively; (r10, r11, r12)c, wherein r10, r11, r12 are independently phenyl, alkyl, optionally substituted, respectively; x═o, s, or nr13, wherein r13 is h; or alkyl or aryl, optionally substituted, respectively; or r5 is r6—co—nr13, wherein r6 and nr13 have the meaning as defined above, or wherein r6 and r13 taken together form a carbon chain having from 2 to 6 carbon atoms; r5 is a 4 to 8 membered n-containing carbon ring, wherein n is linked to m; and r4 is a residue o—si(o—)3, and represents silica to which m is linked forming a m-o—si(o—)3 moiety, preferably wherein silica is comprised in a solid support; under the proviso that a compound in which r1=2,6-diisopropylphenyl, r5 dimethylpyrrol-1-yl, r2=tbu, and r3═h is excluded.. .
Ximo Ag


05/05/16
20160122287 

Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride


A hitherto unknown crystalline form of (−)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.. .
Gruenenthal Gmbh


05/05/16
20160122277 

Process of production of dehydrolinalyl acetate (ii)


The present invention is related to a novel and improved process for the production of dehydrolinalyl acetate (dla), which 1upac name is acetic acid 1-ethynyl-1,5-dimethyl-hex-4-enyl ester, starting from dehydrolinalool (dll), which 1upac name is 3,7-dimethyloct-6-en-1-yn-3-ol, by acetylation.. .
Dsm Ip Assets B.v.


05/05/16
20160120988 

Pazopanib formulation


A granulation formulation of 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.. .
Novartis Ag


05/05/16
20160120937 

Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans


Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one trail receptor agonist.

05/05/16
20160120871 

Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent


The present invention relates to a combination comprising (a) a phosphatidylinositol 3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salts thereof, and (b) a microtubule destabilizing agent for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a tumor disease comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the treatment of a tumor disease; and a commercial package thereto.. .
Novartis Ag


05/05/16
20160120177 

Agrochemical formulations


A liquid herbicide composition is provided comprising at least an electrolytic agrochemical active; at least an alkyl n,n-dimethylamine n-oxide, and at least one (c9-c20) alkyl sulfosuccinic acid mono ester salt.. .
Upl Limited


04/28/16
20160115405 

Organic fuel and waste reformer


This invention pertains to the non-catalytic oxygenated steam reforming of organic matter to produce a gas mixture rich in hydrogen, carbon monoxide and carbon dioxide. The reforming gas is used for production of methane, methanol, dimethyl ether, oxygen, carbon dioxide, and other compounds via downstream processing catalytic gas-phase processes and electrolysis.
Pioneer Astronautics


04/28/16
20160115165 

Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders


Crystalline form, form hi.5-4, of n,n-di-cyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (compound i) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising form hi.5-4 of compound i as well as a method of using the form hi.5-4 of compound i in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


04/28/16
20160115113 

Aerobic oxidative esterification of sugar-derived 1,4-disubstituted benzene for direct synthesis of dimethylterephthalate


This invention relates to a dimethylterephthalate production process comprising reacting substituted furan with ethylene under cycloaddition reaction conditions and in the presence of a cycloaddition catalyst to produce a bicyclic ether, dehydrating the bicyclic ether to produce a substituted phenyl, dissolving said substituted phenyl in methanol, and oxidizing and esterifying the substituted phenyl in the presence of an oxidative esterification catalyst to form dimethylterephthalate. Importantly, the process does not include oxidizing the substituted phenyl to form terephthalic acid..
Exxonmobil Chemical Patents Inc.


04/28/16
20160115038 

Method for making molecular sieve ssz-102


A method for making a new crystalline molecular sieve designated ssz-102 is disclosed using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent. Ssz-102 has esv framework topology..
Chevron U.s.a. Inc


04/28/16
20160115037 

Molecular sieve ssz-102


A new crystalline molecular sieve designated ssz-102 having esv framework topology is disclosed. Ssz-102 is synthesized using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent..
Chevron U.s.a. Inc


04/28/16
20160114313 

Processes using molecular sieve ssz-102


Uses are disclosed for a new crystalline molecular sieve designated ssz-102 synthesized using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent. Ssz-102 has esv framework topology..
Chevron U.s.a. Inc


04/28/16
20160113275 

Tobacco axillary bud growth inhibitor and inhibiting tobacco axillary bud growth


An inhibitor for tobacco axillary bud growth, containing chlorthal-dimethyl and aliphatic alcohol selected from decyl alcohol, 2-ethyl hexanol and geraniol in combination; and a method for inhibiting tobacco axillary bud growth, which includes applying the inhibitor for tobacco axillary bud growth.. .
Sds Biotech K. K.


04/21/16
20160111276 

Vapor deposition of metal oxides, silicates and phosphates, and silicon dioxide


Metal silicates or phosphates are deposited on a heated substrate by the reaction of vapors of alkoxysilanols or alkylphosphates along with reactive metal amides, alkyls or alkoxides. For example, vapors of tris(tert-butoxy)silanol react with vapors of tetrakis(ethylmethylamido)hafnium to deposit hafnium silicate on surfaces heated to 300° c.

04/21/16
20160111272 

Vapor deposition of silicon-containing films using penta-substituted disilanes


Disclosed are methods of depositing silicon-containing films on one or more substrates via vapor deposition processes using penta-substituted disilanes, such as pentahalodisilane or pentakis(dimethylamino)disilane.. .

04/21/16
20160108163 

Polylactic acid (pla) with low moisture vapor transmission rates by grafting through of hydrophobic polymers directly to pla backbone


Polylactic acid-backbone graft and bottlebrush copolymers with low moisture vapor transmission rates are synthesized by polymerizing a lactide-functionalized hydrophobic macromonomer using ring-opening polymerization (rop). In some embodiments of the present invention, the macromonomer is a lactide-functionalized hydrophobic polymer that may be synthesized by, for example, polymerizing a hydrophobic monomer (e.g., a fluorinated vinyl monomer such as 2,2,2-trifluroethyl methacrylate) capable of undergoing radical polymerization (e.g., styrenic, vinylic, acrylic, etc.) using a brominated lactide initiator via atom transfer radical polymerization (atrp).

04/21/16
20160107990 

4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator


Disclosed are an alpha 7 nachr receptor modulator compound, 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical compositions comprising the compound or a salt thereof, and a method of treating various diseases, disorders or conditions, for example, alzheimer's disease, mild cognitive impairment, senile dementia, vascular dementia, dementia of parkinson's disease, and attention deficit disorder.. .

04/21/16
20160107134 

Amphoteric ester sulfonates


Disclosed are a variety of amphoteric ester sulfonates, including 3-(n,n-dimethyl-cocoylpropylammonio-1-yl)-2-hydroxypropanesulfonate. These amphoteric ester sulfonates can be advantageously prepared in high yield and purity by a two-step chemoenzymatic process, and have excellent surfactant properties..

04/21/16
20160106835 

Combination therapies for cancer


A novel combination comprising a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a pd-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf and/or immune modulation through pd-1 is beneficial, e.g., cancer.. .

04/21/16
20160106641 

Stable compositions for whitening teeth and methods of using same


A thickened tooth whitening composition in gel form comprises hydrogen peroxide or a hydrogen peroxide precursor, and a thickening polymer or copolymer comprising a pendant sulfonic acid group moiety, preferably hydroxyethyl acrylate/sodium acryloyldimethyltaurate copolymer. Gels in accordance with the invention exhibit an extended shelf life without requiring refrigeration or other special storage conditions.

04/14/16
20160102300 

Immobilized proline-specific endoprotease


The present invention relates to immobilized proline-specific endoprotease, wherein the proline-specific endoprotease is immobilized on a carrier comprising methacrylate which has been functionalized with amino dimethylene, and wherein the carrier has a particle size range of 100 to 400 μm. The invention also relates to a process for producing beer comprising the steps of preparing a mash, fermenting the beer, and stabilizing the beer, wherein the beer is incubated with the immobilized proline-specific endoprotease..

04/14/16
20160102191 

Silicone rubber composition and manufacturing method thereof


Disclosed are a silicone rubber composition and a preparation method thereof. The silicone rubber composition comprises a polydimethylvinylsiloxane, a silica filler, a polymethylvinylsiloxane oil, a hydrogen-modified polyorganosiloxane, a platinum-based catalyst, and a polymethylhydrogensiloxane vulcanizing agent..

04/14/16
20160102085 

Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles


This invention relates to novel (cyano-dimethyl-methyl)-isoxazolesand-[1,3,4]thiadiazoles and their use as cb2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of cb2 receptor mediated disorders or conditions.. .

04/14/16
20160102048 

N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)


This disclosure relates to n-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino)naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula i.

04/14/16
20160102032 

Apparatus and process for producing gasoline, olefins and aromatics from oxygenates


Apparatuses and processes for converting an oxygenate feedstock, such as methanol and/or dimethyl ether, in a fluidized bed containing a catalyst to hydrocarbons, such as gasoline boiling components, olefins and aromatics are provided herein.. .

04/14/16
20160102031 

Apparatus and process for producing gasoline, olefins and aromatics from oxygenates


Apparatuses and processes for converting an oxygenate feedstock, such as methanol and dimethyl ether, in a fluidized bed containing a catalyst to hydrocarbons, such as gasoline boiling components, olefins and aromatics are provided herein.. .

04/14/16
20160101986 

Method for making euo framework type molecular sieves


A method for preparing euo framework type molecular sieve is disclosed using an n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent. The euo framework type molecular sieve, in its as-synthesized form, contains in its intracrystalline pores the n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication..

04/14/16
20160101062 

Treatment and prevention of cardiovascular disease and thrombosis


Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (cvd), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of tma in the gut, such as 3,3-dimethyl-1-butanol (dmb) or other compounds represented by formula i or as shown in figs.

04/07/16
20160097349 

Mixed fuel supply system for internal combustion engine, vehicle, and mixed fuel supply internal combustion engine


A mixed fuel supply system includes a dimethyl ether (“dme”) tank which stores dme, a dme supply path which supplies the dme and a light oil supply system. The dme supply path is connected to a transfer path between a feed pump and a fuel injection pump.
Isuzu Motors Limited


04/07/16
20160097015 

Bearing material


A plastic bearing material of a bearing may include a block copolymer. The block copolymer may include structural blocks of two or more different polymers.

04/07/16
20160096863 

Methods of preparing intermediate of fluticasone propionate


A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(n,n-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth metal hydroxide, or a mixture thereof to cleave an amide from the 17β-[(n,n-dimethyl carbamoyl)thio]carbonyl compound; treating the solution to separate an aqueous portion; and adding an acid to the aqueous portion to obtain the thioic acid intermediate of fluticasone propionate. A method of preparing fluticasone propionate includes preparing the thioic acid intermediate of fluticasone propionate, and alkylating the thioic acid intermediate of fluticasone propionate to prepare the fluticasone propionate..
Amphastar Pharmaceuticals Inc.


04/07/16
20160096838 

Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders


Crystalline form, form t2h1.5-4, of n,ndicyclopropyl-4-(1,5-dimethyl-1 hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (compound (i)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising form t2h1.5-4 of compound (i) as well as a method of using the form t2h1.5-4 of compound (i) in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


04/07/16
20160096816 

Method of preparing intermediate of salmeterol


A method of preparing an intermediate of salmeterol (compound 1, 2-amino-1-(2,2-dimethyl-4h-1,3-benzodioxin-6-yl)ethanol) includes: reacting compound 2 with 2-methoxypropene in a first organic solvent to produce a reaction solution including compound 3, compound 2 including a 2-bromo precursor of compound 1; reacting compound 3 with a nitrogen source to produce compound 4; reacting compound 4 with sodium borohydride in a second organic solvent to produce compound 5; and debenzylating compound 5 by ammonium formate/palladium-carbon catalytic transfer hydrogenation in a third organic solvent to produce compound 1. A method of preparing salmeterol includes preparing compound 1, and reacting compound 1 to prepare salmeterol..
Amphastar Pharmaceuticals Inc.


04/07/16
20160096807 

Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator


The present disclosure relates to co-crystals comprising n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits..
Vertex Pharmaceuticals Incorporated


04/07/16
20160095890 

Composition for the treatment of joint conditions


The present invention relates to a composition for improving the health status of various joints in the human body. The composition includes at least one plant extract as fatty base with active role, at least one extract from plants with anti-microbial properties, at least one extract from plants with analgesic and/or anti-inflammatory properties, and at least one extract from plants with anti-rheumatic and regenerative properties, to which dimethylsulfoxide, allantoin and/or potassium alum may be added.

04/07/16
20160095859 

Combination therapies for overcoming resistance to mitotic agents during chemotherapy


This disclosure relates to the uses of compounds that target an interaction between chfr and parp1. In certain embodiments, the disclosure relate to treating cancer by administering a mitotic inhibitor such as a taxane and a vinca alkaloid in combination with a compound that inhibits chfr and parp1 interactions, such as 5-((1-benzyl-1h-indol-3-yl)methylene)-1-(3,4-dimethylphenyl)pyrimidine-2,4,6(1h,3h,5h)-trione, derivatives or salts thereof, optionally in further combination with a third anti-cancer agent..
Emory University


03/31/16
20160090435 

Block copolymer, forming the same, and forming pattern


Wherein com1 and com2 are independently selected from a polystyrene moiety, polymethylmethacrylate moiety, polyethylene oxide moiety, polyvinylpyridine moiety, polydimethylsiloxane moiety, polyferrocenyldimethylsilane moiety, and polyisoprene moiety, r1 is hydrogen or an alkyl group with 1 to 10 carbon atoms, ph is a phenyl group, a is 1 to 50, r2 is hydrogen or an alkyl group with 1 to 10 carbon atoms, and b is 1 to 50.. .

03/31/16
20160090385 

Crystalline forms of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboximide for the treatment of myeloproliferative disorders


Crystalline form, form t1h1.5-4, of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (compound (i)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising form t1h1.5-4 of compound (i) as well as a method of using the form t1h1.5-4 of compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis..
Bristol-myers Squibb Company


03/31/16
20160090359 

Crystalline forms of an nk-1 antagonist


The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-n,2-dimethyl-n-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an nk-1 antagonist useful in the treatment of induced vomiting and other disorders.. .
Helsinn Healthcare Sa


03/31/16
20160090354 

Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto


A novel solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “atr-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. Atr-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (acc), congenital adrenal hyperplasia (cah) and cushing's syndrome..
Atterocor, Inc.


03/31/16
20160090308 

A process for making molecular sieves


The invention relates to a process for preparing molecular sieves, such as zsm-57, using one or more structure directing agents selected from the group consisting of n1,n1,n5,n5-tetraethyl-n1,n5-dimethylpentane-1,5-diamininum, 1-ethyl-1-(5-(1-methylpiperidin-1-ium-1-yl)pentyl)piperidin-1-ium, 1,1′-(hexane-1,6-diyl)bis(1-ethylpiperidin-1-ium), and 1,1-diethylpyrrolidin-1-ium.. .
Exxonmobil Chemical Patents Inc.


03/31/16
20160089434 

Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor


A novel combination comprising the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and/or a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and an anti-pd-l1 antibody; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf and/or neutralizing or inhibiting the interaction between pd-l1 and its receptor, e.g. Pd-1, is beneficial, eg.
Novartis Ag


03/31/16
20160089387 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/31/16
20160089386 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/24/16
20160087066 

Vapor deposition of metal oxides, silicates and phosphates, and silicon dioxide


Metal silicates or phosphates are deposited on a heated substrate by the reaction of vapors of alkoxysilanols or alkylphosphates along with reactive metal amides, alkyls or alkoxides. For example, vapors of tris(tert-butoxy)silanol react with vapors of tetrakis(ethylmethylamido)hafnium to deposit hafnium silicate on surfaces heated to 300° c.
President And Fellows Of Harvard College


03/24/16
20160083598 

White ink


An ink comprising: (a) from 1 to 25 parts of surface treated titanium dioxide; (b) from 8 to 25 parts of a first solvent selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol and dipropylene glycol; (c) from 2 to 12 parts of a second solvent selected from the group consisting of 2-pyrrolidone, n-methyl-2-pyrrolidone, n-ethyl-2-pyrrolidone, n-cyclohexyl-2-pyrrolidone and n,n-dimethylacetamide; (d) from 15 to 45 parts of glycerol; (e) from 0.1 to 2 parts of an acetylenic surfactant; (f) from 0.001 to 2 parts of 1,2-benzisothiazolin-3-one; (g) from 0 to 20 parts of polymer particles; and (h) the balance to 100 parts water.. .
Fujifilm Imaging Colorants, Inc.


03/24/16
20160083384 

Salts and crystalline forms of an apoptosis-inducing agent


Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic bcl-2 family proteins, for example cancer.. .
Abbvie Inc.


03/24/16
20160083373 

Method for preparing afatinib and intermediate thereof


Revealed in the present invention is a method for preparing afatinib (i): using 2-nitrile-4-[4-(n,n-dimethylamino)-i-oxo-2-buten-i-yl]amino-5-[(s)-(tetrahydrofuran-3-yl)oxy]aniline (ii) and 4-fluoro-3-chloroaniline (iii) as starting materials, and respectively performing a condensation and cyclization reaction with n,n-dimethylformamide dimethyl acetal (iv) to prepare afatinib (i), wherein the method significantly reduces the manufacturing steps of afatinib and greatly lower the costs. In addition, also provided in the present invention is a method for preparing an intermediate of afatinib, wherein the method has a stable process, uses readily available starting materials, has a low cost, and all the reactions are classic reactions, suitable for meeting amplification requirements in the industry..
Suzhou Miracpharma Technology Co., Ltd.


03/24/16
20160083359 

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment


1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on sert, 5-ht3 and 5-ht1a and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.. .
H. Lundbeck A/s


03/24/16
20160083340 

Method of purifying dimethyl sulfoxide


A method of purifying dimethyl sulfoxide economically and at good yield satisfies the specifications of the united states pharmacopoeia and reduces odor. The method includes distilling a solution having 35 parts by weight or more of water admixed per 100 parts by weight of raw dimethyl sulfoxide..
Toray Fine Chemicals Co., Ltd.


03/17/16
20160077066 

Analytical detecting fuel markers


A gas chromatographic method for detecting a marker compound in a fuel by (a) introducing a sample of fuel into a first capillary column coated with a stationary phase based on polydimethylsiloxane and allowing the sample to flow through the first column to produce a first effluent; (b) allowing the first effluent to pass through a detector and identifying a retention time range in it which includes a retention time of the marker compound; (c) introducing only a portion of the first effluent stream which is within the retention time range into a second capillary column coated with either (i) an ionic sorbent or (ii) a polyethylene glycol, and allowing said portion to flow through the second capillary column to produce a second effluent stream; and (d) allowing the second effluent to pass through a detector; wherein the marker compound has formula ar(r2)m(or1)n and is present in the fuel at a level from 0.01 ppm to 100 ppm.. .
Dow Global Technologies Llc


03/17/16
20160075632 

Process of production of dehydrolinalyl acetate (i)


The present invention is related to a novel and improved process for the production of dehydrolinalyl acetate (dla), which iupac name is acetic acid 1-ethynyl-1,5-dimethyl-hex-4-enyl ester, starting from dehydrolinalool (dll), which iupac name is 3,7-dimethyloct-6-en-1-yn-3-ol, by catalytic acetylation.. .
Dsm Ip Assets B. V.


03/10/16
20160068674 

Imprint material


There is provided an imprint material that has sufficient adhesion to film substrates and excellent scratch resistance, and can be readily released from a mold at the time of mold release. An imprint material including: (a) a specific acrylamide such as n,n′-dimethylacrylamide; (b) a compound having alkylene oxide units and having 2 to 6 polymerizable groups at the ends of the compound, in which the alkylene oxide units are ethylene oxide units, propylene oxide units, or a combination thereof; and (c) a photopolymerization initiator..
Nissan Chemical Industries, Ltd.


03/10/16
20160068511 

Maleate salts of (e)-n--4-(dimethylamino)-2-butenamide and crystalline forms thereof


The present invention relates to maleate salt forms of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family..
Wyeth Llc


03/10/16
20160068403 

Method for preparing zeolite ssz-52 using computationally predicted structure directing agents


A method is disclosed for preparing zeolite ssz-52 using a computationally predicted organic structure directing agent. The computationally predicted structure organic directing agent is an organic structure directing agent other than an n,n-diethyl-5,8-dimethyl-azonium bicyclo[3.2.2.]nonane cation, and the difference in stabilization energy between the organic structure directing agent other than an n,n-diethyl-5,8-dimethyl-azonium bicyclo[3.2.2.]nonane cation and the n,n-diethyl-5,8-dimethyl-azonium bicyclo[3.2.2.]nonane cation is no more than 2.5 kj mol−1 si..
Chevron U.s.a. Inc


03/10/16
20160067956 

Release agent composition for improved coefficient of friction


A functional amine release agent displaying reduced coefficient of friction as compared to standard silicone oils, comprises a polydimethylsiloxane oil and a functional amine selected from the group consisting of pendant propylamines and pendant n-(2-aminoethyl)-3-aminopropyl. The concentration of functional amine to polydimethylsiloxane oil is approximately less than 0.0001 meq/g.
Xerox Corporation


03/10/16
20160067266 

Stabilized composition for treating psoriasis


A storage stable ointment of the present invention comprises a vitamin d compound, a corticosteroid, and an n,n-di(c1-c8) alkylamino substituted, (c4-c18) alkyl (c2-c18) carboxylic ester a (c1-c4)-alkyl (c8-c22) carboxylic ester in a petrolatum ointment base, and optionally containing mineral oil and/or tocopherol. Preferably, the vitamin d compound is calcipotriene, the corticosteroid is selected from the group consisting of clobetasol propionate and betamethasone dipropionate, and the n,n-di(c1-c8) alkylamino substituted, (c4-c18) alkyl (c2-c18) carboxylic ester comprises dodecyl 2-(n,n-dimethylamino)-propionate (ddaip)..
Nexmed Holdings, Inc.


03/10/16
20160067248 

Combinations


The present invention relates to a method of treating ovarian cancer in a female human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a ovarian cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and 2-[(5-chloro-2-[[3-methyl-1-(1-methylethyl)-1h-pyrazol-5-yl]amino]-4-pyridinyl)amino]-n-methoxybenzamide, or a pharmaceutically acceptable salt thereof, and optionally 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}, to a human in need thereof..
Board Of Regents, The University Of Texas System


03/10/16
20160067206 

Composition for preventing or treating renal fibrosis comprising dimethylfumarate as active ingredient


The present invention relates to a composition for preventing or treating renal fibrosis comprising dimethylfumarate (dmf) as an active ingredient. The dmf according to the present invention has an excellent effect of reducing renal fibrosis by activating nrf2 to inhibit tgf-β/smad signaling, and thus is useful for preventing or treating renal fibrosis..
Kyungpook National University Hospital


03/03/16
20160060763 

Chemical vapor deposition process and coated article


A chemical vapor deposition process and coated article are disclosed. The chemical vapor deposition process includes positioning an article in a chemical vapor deposition chamber, then introducing a deposition gas to the chemical vapor deposition chamber at a sub-decomposition temperature that is below the thermal decomposition temperature of the deposition gas, and then heating the chamber to a super-decomposition temperature that is equal to or above the thermal decomposition temperature of the deposition gas resulting in a deposited coating on at least a surface of the article from the introducing of the deposition gas.
Silcotek Corp.


03/03/16
20160060391 

Copolymer based on dimethyl carbonate and preparing the same


A copolymer based on dimethyl carbonate and a method of preparing the same are provided. The copolymer based on dimethyl carbonate has a unit from dimethyl carbonate, diols, and a modification monomer.
National Cheng Kung University


03/03/16
20160060375 

Tulipalin a-based hydroxyl-functionalized polymers, and engineered materials prepared therefrom


A tulipalin a-based hydroxyl-functionalized (hf) polymer is synthesized by converting, via a ring opening reaction, poly(tulipalin a) or poly(tulipalin a-co-acrylic) in the presence of a nucleophilic monomer and a catalyst. The nucleophilic monomer may be, for example, a nitrogen-containing monomer such as dimethylamine.
International Business Machines Corporation


03/03/16
20160060215 

New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine


The present invention provides new intermediate compounds or formulae (iii) and (iva), and salts thereof, and their use in a new synthetic process for the production of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (vortioxetine) an experimental drug under development for the treatment of depression and anxiety.. .
Lek Pharmaceuticals D.d.


02/25/16
20160053224 

Methods of cell separation


The present invention relates to the use of a combination of: (i)a macromolecular erythrocyte sedimentation enhancer, and (ii) dimethyl sulphoxide (dmso), dimethylglycine (dmg) and/or valine; to recover non-erythrocyte blood cells from a blood cell-containing sample and/or to prime non-erythrocyte blood cells to protect their integrity in subsequent cryopreservation step(s).. .
Cells 4 Life Group Llp


02/25/16
20160052960 

Process for the preparation of drospirenone


A process is disclosed wherein, using either 17a-(3-hydroxypropyl)-6p,7p;15p,16p-dimethylene-5p-androstane-3p,5,17p-triol (ii) or 3β,5̂iîκ̂-6β,7β;15β,16β-dimethylene-5β,17α-pregnane-21,17-carbolactone (iii) as starting material, through a single-step reaction it is obtained drospirenone (i), a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action.. .
Industtiale Chimica S.r.l.


02/25/16
20160052857 

Carbonylation process


A process for the production of methyl acetate by carbonylating dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein the process is carried out with a molar ratio of hydrogen to carbon monoxide of at least 1 and the catalyst has been calcined at a temperature of from about 375° c. To about 475° c..
Bp Chemicals Limited


02/25/16
20160051608 

Anti-cancer extract and compounds


The present invention relates to a new approach for treating a cancer or fibrosis, such as hepatocellular carcinoma, or liver fibrosis using an extract from a plant of graptopetalum sp., rhodiola sp., or echeveria sp., and prepared by extracting the plant with dimethyl sulfoxide (dmso), its fraction or the compound isolated from the extract.. .
National Yang-ming University


02/18/16
20160049693 

Electrolytes for rechargeable batteries


Provided are novel electrolytes for use in rechargeable lithium ion cells containing high capacity active materials, such as silicon, germanium, tin, and/or aluminum. These novel electrolytes include one or more pyrocarbonates and, in certain embodiments, one or more fluorinated carbonates.
Amprius, Inc.


02/18/16
20160049663 

Ionomer solution containing anion-exchange resin dissolved in solvent


Provided is an ionomer solution including an anion-exchange resin and a solvent. The anion-exchange resin is dissolved in the solvent, the anion-exchange resin includes a matrix resin and an anion-exchange group, the matrix resin includes a styrene elastomer, and the anion-exchange group is a quaternary ammonium salt group having at least one unit derived from an amine selected from the group consisting of an n,n-dimethylalkylamine having an alkyl group having two or more carbon atoms and a bicycloalkane having a nitrogen atom at a bridgehead position..
Nitto Denko Corporation


02/18/16
20160049261 

Supercapacitor


Embodiments provide a hybrid supercapacitor exhibiting high energy and power densities enabled by a high-performance lithium-alloy anode coupled with a porous carbon cathode in an electrolyte containing lithium salt. Embodiments include a size reduced silicon oxide anode, a boron-doped silicon oxide anode, and/or a carbon coated silicon oxide anode, which may improve cycling stability and rate performance.
The Penn State Research Foundation




Dimethyl topics: Physiologic, Hydrochloric Acid, Fresnel Zone, Aberration, Ophthalmic, Liquid Crystal, Imaging System, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Chloric Acid, Tartaric Acid, Fumaric Acid, Antagonist, Bradykinin, Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2676

4613

0 - 1 - 103